Invasive Candidiasis clinical trials at University of California Health
3 in progress, 2 open to eligible people
MARIO Study: IV Echinocandin Followed by Oral Ibrexafungerp or Oral Fluconazole
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
at UC Davis
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
open to eligible people ages 18 years and up
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
at UCLA
Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases
Sorry, in progress, not accepting new patients
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
at UC Davis UCSF
Last updated: